Cardiol Therapeutics Statistics
Share Statistics
Cardiol Therapeutics has 81.60M shares outstanding. The number of shares has increased by 25.32% in one year.
| Shares Outstanding | 81.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 16.77% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 77.72M |
| Failed to Deliver (FTD) Shares | 47.97K |
| FTD / Avg. Volume | 12.74% |
Short Selling Information
The latest short interest is 814.79K, so 1% of the outstanding shares have been sold short.
| Short Interest | 814.79K |
| Short % of Shares Out | 1% |
| Short % of Float | 1.05% |
| Short Ratio (days to cover) | 1.37 |
Valuation Ratios
The PE ratio is -2.52 and the forward PE ratio is -6.16.
| PE Ratio | -2.52 |
| Forward PE | -6.16 |
| PS Ratio | 0 |
| Forward PS | 130.8 |
| PB Ratio | 2.51 |
| P/FCF Ratio | -2808.87 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cardiol Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.36, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.36 |
| Quick Ratio | 4.36 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.56 |
| Cash Flow / Debt | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1% and return on capital (ROIC) is -104.8%.
| Return on Equity (ROE) | -1% |
| Return on Assets (ROA) | -0.77% |
| Return on Capital (ROIC) | -104.8% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.28M |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 20.19% in the last 52 weeks. The beta is 0.7, so Cardiol Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 20.19% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 35.65 |
| Average Volume (20 Days) | 376.54K |
Income Statement
| Revenue | n/a |
| Gross Profit | -248.35K |
| Operating Income | -29.79M |
| Net Income | -28.13M |
| EBITDA | -29.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.44 |
Balance Sheet
The company has 34.93M in cash and 174.34K in debt, giving a net cash position of 34.76M.
| Cash & Cash Equivalents | 34.93M |
| Total Debt | 174.34K |
| Net Cash | 34.76M |
| Retained Earnings | -142.58M |
| Total Assets | 17.52M |
| Working Capital | 10.33M |
Cash Flow
In the last 12 months, operating cash flow was -25.18K and capital expenditures -64.31, giving a free cash flow of -25.24K.
| Operating Cash Flow | -25.18K |
| Capital Expenditures | -64.31 |
| Free Cash Flow | -25.24K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRDL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.2% |
| FCF Yield | -0.02% |
Analyst Forecast
The average price target for CRDL is $9, which is 620% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 620% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -10.63 |
| Piotroski F-Score | 2 |